VIR Key Statistics, Chart & Performance
The current stock price of VIR is 6.42 USD. In the past month the price increased by 8.26%. In the past year, price decreased by -19.35%.
VIR Latest News, Press Relases and Analysis
VIR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About VIR
Company Profile
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 408 full-time employees. The company went IPO on 2019-10-11. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. The company also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. The company also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Company Info
VIR BIOTECHNOLOGY INC
1800 Owens Street, Suite 900
San Francisco CALIFORNIA 94158 US
CEO: George Scangos
Employees: 408
Phone: 14159064324
VIR BIOTECHNOLOGY INC / VIR FAQ
What does VIR do?
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 408 full-time employees. The company went IPO on 2019-10-11. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. The company also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. The company also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Can you provide the latest stock price for VIR BIOTECHNOLOGY INC?
The current stock price of VIR is 6.42 USD. The price increased by 0.47% in the last trading session.
Does VIR stock pay dividends?
VIR does not pay a dividend.
What is the ChartMill rating of VIR BIOTECHNOLOGY INC stock?
VIR has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is VIR BIOTECHNOLOGY INC (VIR) stock traded?
VIR stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of VIR BIOTECHNOLOGY INC (VIR)?
VIR BIOTECHNOLOGY INC (VIR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.61).
Can you provide the market cap for VIR BIOTECHNOLOGY INC?
VIR BIOTECHNOLOGY INC (VIR) has a market capitalization of 893.21M USD. This makes VIR a Small Cap stock.
VIR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to VIR. When comparing the yearly performance of all stocks, VIR turns out to be only a medium performer in the overall market: it outperformed 63.46% of all stocks.
VIR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VIR. No worries on liquidiy or solvency for VIR as it has an excellent financial health rating, but there are worries on the profitability.
VIR Financial Highlights
Over the last trailing twelve months VIR reported a non-GAAP Earnings per Share(EPS) of -3.61. The EPS increased by 7.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.01% | ||
| ROE | -62.76% | ||
| Debt/Equity | 0 |
VIR Forecast & Estimates
14 analysts have analysed VIR and the average price target is 17.57 USD. This implies a price increase of 173.62% is expected in the next year compared to the current price of 6.42.
For the next year, analysts expect an EPS growth of 13.12% and a revenue growth -83.95% for VIR